
Capstan Medical is developing a robotics platform and catheter-delivered heart implants for mitral and tricuspid valve replacements. [Photo courtesy of Capstan Medical]
Capstan Medical is a medtech startup at the intersection of surgical robotics and transcatheter heart valve replacement, two established innovations that surgeons at one time thought were neither necessary nor feasible.
Founded by veterans of surgical robotics leader Intuitive Surgical and backed by Intuitive Ventures, Capstan Medical recently announced the first-in-human cases using its nitinol-enabled mitral valve implant, novel delivery catheter, and custom-built robotic platform. The team is also working on a system for tricuspid valve replacement.
Nitinol innovation: Download our free special report featuring nitinol expertise and tips from Capstan and other medical device OEMs
Greg Dachs joined Capstan this year as R&D head and previously worked on next-generation systems, instruments and technology at Intuitive. He’s particularly passionate about user experience, the trade-offs that are inherent in surgical robotics design and engineering, and medtech innovations that can improve or save the lives of patients across the globe.
Dachs offered a unique look into Capstan’s technology, offered his expertise on surgical robotics R&D, and took questions from our live audience in an April 2025 Medical Design & Outsourcing webinar, which you can watch on-demand anytime for free.
But if you’d rather read or skim my conversation with Dachs, I’ve transcribed his comments and lightly edited them for space and clarity below. I’ve also placed his answers to questions from our audience throughout the transcript for ease of reading and flow.
I’m always interested to hear how people in medtech got into this industry, so what’s your story?

Greg Dachs is the head of R&D at Capstan Medical [Photo courtesy of Carbon]
It’s a personal one, really. Back in undergrad, I was studying robotics and controls and I was always excited about that technology, but didn’t really have any specific thing I was aimed at. I was 20 and I got diagnosed with a tumor in my knee and had to get a biopsy of it. The way they do those biopsies is you go into a CT scan, somebody comes in and draws a target on your knee where they want to stick a giant needle, and then they stick the needle in and biopsy it — after they tell you that if they miss, it’s going to be the worst thing you’ve ever felt in your life. So that was a fun experience. I left that experience thinking a robot should be able to do this better than somebody drawing literally with a Sharpie on the back of my knee. And that had looking at what was going on in the world. Intuitive in 2004 or so was early, but they were doing cases, and there were a few other startups playing in that space. So I saidI want to aim my career at that type of thing, decided to go to grad school and study medical robotics at Purdue, and then was able to get into the research group at Intuitive Surgical and really start focusing on that.
Can you tell us a little bit about your career at Intuitive and what you worked on?
When I joined the applied research group, it was a small team of five or seven people, and we were trying to look at technology that was five to 10 years out in the future. The first thing I looked at was force feedback for instruments, and it is now commercial in Da Vinci 5, which is pretty cool to see. It took a while to get that stuff dialed in, but it’s cool to see the full circle on some of the very earliest stuff I worked on in my career there. I then moved on from that. I got really excited to work on stuff that was a little bit nearer term, something that was more directly in the product pipeline and moved to a team working on what became their first stapler product: the back end of that stapler, the gears and mechanisms and things in there and some of the transmission components that send all the all the energy down to the stapler to actually fire it. For the bulk of my time I got pulled off of that to go work on what became Xi. It was a handful of us working with basically a blank whiteboard to say what does the next-generation system look like? We need narrower, more capable instruments and a bunch of other requirements that we were aimed at. And I was on the group that was responsible for the instrument back end, the sterile adapter and the carriage. It was two mechanical engineers, an electrical engineer and some controls people, and we started working on that from a blank sheet of paper and then started to build the teams up around it and got it out into the world. It’s pretty cool to see that out there now doing millions of procedures a year. It’s pretty wild to think where we were and where they are now. I also worked on a few other things some instruments, some stuff on SP, things like that.
And now you’re at Capstan. What does your job entail? And what’s an average day like as R&D head?

This illustration depicts a transcatheter heart valve replacement patient using Capstan Medical robot-assisted delivery system. [Illustration courtesy of Capstan Medical]
I cleared three months this week [at the time of this interview in April], so I’m still reasonably fresh. A lot of my initial time at Capstan has been learning: learning the team, learning the dynamics, learning the procedures. The work that I did at Intuitive was more general surgery, abdominal stuff. I know what a heart is, what it does, where it is in the body, but there was a lot of kind of basics to get under my belt. I spent a lot of time watching YouTube videos and procedure videos, asking questions and like things like that to understand what’s going on. I have a little bit better of a handle now on what’s going on there. Pivoting more toward what’s the job, what we’re doing right now is a lot of planning work and architecture work on what the future of our system looks like. We did two first-in human cases about two months ago in Chile. They were successful. The patients are doing well. I had basically nothing to do with that, but I got to be here and watch it. That that equipment is early, it’s what it needs to be to do a safe and effective first-in-human case, but, but now we get to do the fun thing of taking what we’ve learned there and what we’ve learned through that development cycle and really figure out what we want our product to look like, what do we want to go into the pivotal clinical trials with, and what do we eventually want to put out there on the market and really scale this thing up. So lots of discussion about what’s the system architecture for that, what’s our software strategy, what are the timelines for this, what’s the budget for it, those big questions to draw some boxes around the product development so that we can go execute.
Can you talk us through the procedure?

This illustration depicts Capstan Medical’s transcatheter heart valve implant emerging from the delivery catheter sheath. [Illustration courtesy of Capstan Medical]
For a mitral valve that is leaking, we go in through the right femoral vein and we start the procedure with a guide wire, typical of transcatheter-based approach. The guidewire snakes its way up into the right atrium of the heart. An interesting thing about mitral valve procedures is you land in the right atrium, but to do the procedure you need to be in the left atrium, so you puncture through the septum that divides the right atrium from the left atrium with that guidewire, making a hole you can go through and send our delivery system through that puncture that you’ve made in the septum. The catheter is steered under robotic control. The the ideal thing here is the physician is basically just pushing go, and as they’re pushing go, the robot is following through the predefined trajectory to get to get to the right spot in the heart. And then we pull back the sheath that covers the implant and the implant is deployed by spinning little capstans — hence the name of the company — to unfurl some sutures that have held the implant closed around the shaft. A key feature of our of our implant is, let’s say you’ve half deployed the the implant and don’t really like exactly where it is, you can retract it a bit and move it around and get to where you like the position of that valve before you finally deploy it and seat it into the end of the mitral annulus. Then the delivery system is withdrawn — again, under robotic control, so it’s able to to follow a predefined and kind of optimal trajectory — and you have a new valve implanted in the heart and you’re good to go.